Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Our pre-clinical data to date suggests a potential clinical use as monotherapy, combination therapy with incretin analogs as well as a maintenance therapy post incretin analog induction treatment.” ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

GLP-1, an incretin hormone secreted by intestinal L ... It also acts on the brain to promote satiety and reduce caloric intake. GLP-1 analogs mimic these actions by activating GLP-1 receptors ...

[51] These, and newer agents, such as incretin analogs and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have been evaluated for effects on β-cell function and insulin sensitivity. In a second ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

GLP-1 is an incretin hormone that helps regulate blood ... Since its discovery in 1984 by Svetlana Mosjov, GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly ...

Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on continu ...